DBXO-1 / Deck Bio - LARVOL DELTA

Preclinical characterization of DBXO-1, a multi-pMHC targeted bispecific T cell engager for major solid tumors (AACR 2026) - "Finally, DBXO-1 mediated potent, dose-dependent cytotoxicity on multiple HLA-A*02:01+ cell lines expressing the target signature, while no activity was observed in absence of either target expression or HLA restriction.Taken together, these data support continued preclinical development of DBXO-1, with the goal of entering a first-in-human clinical trial in 2027. Initial clinical development is anticipated in biomarker-selected patient populations across major solid tumors, including non-small cell lung, head and neck, and gastroesophageal cancers."

Bispecific • First-in-human • IO biomarker • Preclinical • Gastroesophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A